CNS Pharmaceuticals, Inc. — Director's Dealing 2019

Nov 8, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CNS Pharmaceuticals, Inc. (CNSP)
CIK: 0001729427
Period of Report: 2019-11-07

Reporting Person: Gumulka Jerzy (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase common stock (right to buy)	$.045	2027-11-08	Common Stock (100000)		Direct

Footnotes

F1: The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or November 8, 2017, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.